Hantavirus cardiopulmonary syndrome (HCPS) is an acute viral infection with a 50% case-fatality that was first recognized in 1993 in New Mexico. Wild rodents transmit it to man. Both North and South America have experienced outbreaks and sporadic cases of HCPS, with 500 cases now recognized. University of New Mexico (UNM) faculty are leaders in the study of HCPS and its ecology, diagnosis, molecular biology, vaccine development, treatment, and pathogenesis. They have traveled to 5 countries in South America, Europe, Israel and Australia to teach courses and conduct workshops, and several have served on NIH and CDC committees on HCPS. UNM currently holds more than $1 million/year in direct costs in federal grants that are directed solely in hantavirus research, as well as other large grants with a hantavirus component. This application describes an International Collaboration in Infectious Diseases Research (ICIDR) program for hantavirus research that matches UNM expertise and resources with similar impressive expertise and resources in Chile. Chilean collaborators are in Santiago at the federal Ministry of Health, including its laboratory branch, the Institute of Public Health (ISP); at Catholic University and University of Chile; and at regional hospitals in Coyhaique and Temuco, two of the primary sites at which HCPS patients are treated. Highly qualified and well-trained collaborators have been identified at all sites. The Ministry of Health rapidly developed resources and manpower to address the HCPS outbreaks, which were first recognized only in August 1997. They have constructed a new laboratory for biological containment work involving the very dangerous Andes hantavirus strain at the ISP and have secured a steady funding stream of $600,000/year from the federal government solely for hantavirus prevention and treatment. Most of these monies can be considered matching funds for the present application. The application involves 4 very strongly linked projects on the ecology of hantaviruses in wild rodents, the interpersonal transmission of HCPS, the genetic basis for severe HCPS and the treatment of HCPS. Two other US universities also provide specific research expertise. Each project pairs strong US technology and experience with highly motivated and experienced Chilean collaborators. Each project has clear and achievable specific aims that will advance the field considerably. A major goal of each project is the rapid and early transfer of technology to Chile to advance scientific knowledge about HCPS for the mutual benefit of both Chilean and US public health. The projects will foster Chilean science well beyond the hantavirus research arena. This ICIDR application is uniquely situated to produce a tremendous return in scientific knowledge because of the substantial cost-matching in Chile and the US and because there is currently relatively little knowledge regarding hantavirus ecology, transmission, disease causation, and treatment.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
868853094
UEI
F6XLTRUQJEN4
Project Start Date
15-September-1999
Project End Date
31-July-2005
Budget Start Date
01-August-2003
Budget End Date
31-July-2005
Project Funding Information for 2003
Total Funding
$300,000
Direct Costs
$253,030
Indirect Costs
$46,970
Year
Funding IC
FY Total Cost by IC
2003
National Institute of Allergy and Infectious Diseases
$300,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U19AI045452-05S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U19AI045452-05S1
Patents
No Patents information available for 3U19AI045452-05S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U19AI045452-05S1
Clinical Studies
No Clinical Studies information available for 3U19AI045452-05S1
News and More
Related News Releases
No news release information available for 3U19AI045452-05S1
History
No Historical information available for 3U19AI045452-05S1
Similar Projects
No Similar Projects information available for 3U19AI045452-05S1